After major ABO-mismatched allogeneic hematopoietic progenitor cell transplantation, erythroid engraftment occurs later in patients with donor blood group A than donor blood group B

Transfusion

Volumn 45, Issue 5, 2005, Pages 779-787

  Schetelig, Johannes ^b   Breitschaft, Astrid ^b   Kröger, Nicolaus ^b   Zabelina, Tatjana ^b   Ebell, Wolfram ^b   Bornhäuser, Martin ^b   Haack, Astrid ^b   Ehninger, Gerhard ^b   Salama, Abdulgabar ^b   Siegert, Wolfgang ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD GROUP A ANTIGEN; BLOOD GROUP B ANTIGEN;

ADOLESCENT; ADULT; AGE; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; BLEEDING DISORDER; BLOOD GROUP A; BLOOD GROUP ABO SYSTEM; BLOOD GROUP B; BLOOD GROUP TYPING; CHILD; CYTOMEGALOVIRUS INFECTION; ERYTHROCYTE TRANSFUSION; FEMALE; GERMANY; GRAFT VERSUS HOST REACTION; HEMOLYTIC ANEMIA; HUMAN; IMMUNOGENICITY; KINETICS; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; RISK FACTOR;

ABO BLOOD-GROUP SYSTEM; ACUTE DISEASE; ADOLESCENT; ADULT; BLOOD GROUPING AND CROSSMATCHING; BLOOD TRANSFUSION; CHILD; CHILD, PRESCHOOL; FEMALE; GRAFT SURVIVAL; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; INFANT; LEUKEMIA, MYELOID; LEUKEMIA, MYELOID, CHRONIC; MALE; MIDDLE AGED; NEUTROPHILS; RETROSPECTIVE STUDIES; RISK FACTORS; SURVIVAL ANALYSIS; TRANSPLANTATION CONDITIONING;

EID: 20844445790     PISSN: 00411132     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1537-2995.2005.04236.x     Document Type: Article

References (23)

1. Worel N, Greinix HT, Schneider B, et al. Regeneration of erythropoiesis after related- and unrelated-donor BMT or peripheral blood HPC transplantation: a major ABO mismatch means problems. Transfusion 2000;40:543-50.
2. Stussi G, Muntwyler J, Passweg JR, et al. Consequences of ABO incompatibility in allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant 2002;30:87-93.
3. Barge AJ, Johnson G, Witherspoon RP, et al. Antibody-mediated marrow failure after allogeneic bone marrow transplantation. Blood 1989;74:1477-80.
4. Gmur JP, Burger J, Schaffner A, et al. Pure red cell aplasia of long duration complicating major ABO-incompatible bone marrow transplantation. Blood 1990;75:290-5.
5. Sniecinski IJ, Oien L, Petz LD, et al. Immunohematologic consequences of major ABO-mismatched bone marrow transplantation. Transplantation 1988;45:530-4.
6. Bensinger WI, Buckner CD, Thomas ED, et al. ABO-incompatible marrow transplants. Transplantation 1982;33:427-9.
7. Mielcarek M, Leisenring W, Torok-Storb B, et al. Graft-versus-host disease and donor-directed hemagglutinin titers after ABO-mismatched related and unrelated marrow allografts: evidence for a graft-versus-plasma cell effect. Blood 2000;96:1150-6.
8. Wernet D, Mayer G. Isoagglutinins following ABO-incompatible bone marrow transplantation. Vox Sang 1992;62:176-9.
9. Lee JH, Lee KH, Kim S, et al. Anti-A isoagglutinin as a risk factor for the development of pure red cell aplasia after major ABO-incompatible allogeneic bone marrow transplantation. Bone Marrow Transplant 2000;25:179-84.
10. Bolan CD, Leitman SF, Griffith LM, et al. Delayed donor red cell chimerism and pure red cell aplasia following major ABO-incompatible nonmyeloablative hematopoietic stem cell transplantation. Blood 2001;98:1687-94.
11. Zaucha JM, Mielcarek M, Takatu A, et al. Engraftment of early erythroid progenitors is not delayed after non-myeloablative major ABO-incompatible haematopoietic stem cell transplantation. Br J Haematol 2002;119:740-50.
12. Kanda Y, Tanosaki R, Nakai K, et al. Impact of stem cell source and conditioning regimen on erythrocyte recovery kinetics after allogeneic haematopoietic stem cell transplantation from an ABO-incompatible donor. Br J Haematol 2002;118:128-31.
13. Przepiorka D, Weisdorf D, Martin P, et al. 1994 Consensus conference on acute GVHD grading. Bone Marrow Transplant 1995;15:825-8.
14. Atkinson K, Horowitz MM, Gale RP, et al. Consensus among bone marrow transplanters for diagnosis, grading and treatment of chronic graft-versus-host disease. Committee of the International Bone Marrow Transplant Registry. Bone Marrow Transplant 1989;4:247-54.
15. Slavin S, Nagler A, Naparstek E, et al. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood 1998;91:756-63.
16. Clift RA, Radich J, Appelbaum FR, et al. Long-term follow-up of a randomized study comparing cyclophosphamide and total body irradiation with busulfan and cyclophosphamide for patients receiving allogenic marrow transplants during chronic phase of chronic myeloid leukemia. Blood 1999; 94:3960-2.
17. Przepiorka D, Khouri I, Thall P, et al. Thiotepa, busulfan and cyclophosphamide as a preparative regimen for allogeneic transplantation for advanced chronic myelogenous leukemia. Bone Marrow Transplant 1999;23:977-81.
18. Bar BM, Van Dijk BA, Schattenberg A, et al. Erythrocyte repopulation after major ABO incompatible transplantation with lymphocyte-depleted bone marrow. Bone Marrow Transplant 1995;16:793-9.
19. Lee JH, Choi SJ, Kim S, et al. Changes of isoagglutinin titres after ABO-incompatible allogeneic stem cell transplantation. Br J Haematol 2003;120:702-10.
20. Mehta J, Powles R, Singhal S, et al. Transfusion requirements after bone marrow transplantation from HLA-identical siblings: effects of donor-recipient ABO incompatibility. Bone Marrow Transplant 1996;18:151-6.
21. Clausen H, Hakomori S. ABH and related histo-blood group antigens; immunochemical differences in carrier isotypes and their distribution. Vox Sang 1989;56:1-20.
22. Ozolek JA, Watchko JF, Mimouni F. Prevalence and lack of clinical significance of blood group incompatibility in mothers with blood type A or B. J Pediatr 1994;125:87-91.
23. Desjardins L, Blajchman MA, Chintu C, et al. The spectrum of ABO hemolytic disease of the newborn infant. J Pediatr 1979;95:447-9.